Gem Aromatics Limited — Q3 FY26 earnings call

Call held 27 Jan 2026

Management summary

GEM Aromatics reported a mixed Q3 FY26, with consolidated revenue at INR 78.9 crores and a net loss of INR 5 crores, primarily due to higher depreciation from the newly commissioned Dahej facility. However, gross and EBITDA margins saw significant quarter-on-quarter improvement, reaching 23% and 8.9% respectively. The company remains optimistic about its long-term growth, targeting INR 1,050-1,100 crores revenue by FY28 with 16-18% EBITDA margins, driven by the Dahej facility's ramp-up and product diversification despite ongoing external headwinds.

Highlights

  • Consolidated Gross Profit margin improved significantly to 23% in Q3 FY26, up from 14% in Q2 FY26.

  • Consolidated EBITDA margin improved to 8.9% in Q3 FY26, up from 3% in Q2 FY26, supported by gradual recovery in mint prices and better customer alignment.

  • The Greenfield Dahej facility successfully commissioned cooling agents (WS23, WS03) and clove/eugenol verticals on December 11, 2025, and completed first-stage audits for various certifications.

  • The company is targeting substantial revenue growth to INR 1,050-1,100 crores by FY28 with healthy EBITDA margins of 16-18%.

  • New products at Krystal (Dahej) are largely tariff-exempt for the US market, and the company is pursuing a dual US+1 strategy to mitigate tariff risks.

Concerns

  • Consolidated net loss for Q3 FY26 was INR 5 crores.

  • Profitability was impacted by higher depreciation of INR 8.7 crores, a non-cash charge, following the capitalization of approximately INR 250 crores capex at the Dahej facility.

  • Revenues were impacted by external headwinds, including tariff-related uncertainty and GST-related changes, influencing customer procurement behavior.

  • Contribution from the newly commissioned Dahej facility was limited in Q3 FY26, as operations were restricted to only approximately 20 days.

Key financials

  1. Consolidated Revenue ₹78.9 Cr
  2. Consolidated Gross Profit ₹18.2 Cr
  3. Consolidated Gross Margin 23% +64.3%QoQ
  4. Consolidated EBITDA ₹7 Cr
  5. Consolidated EBITDA Margin 8.9% +196.7%QoQ
  6. Consolidated Net Loss ₹5 Cr

What they filed

Q1 FY27: revenue up 12.8%, net profit down 198.6% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue112 97 202 88 90 −20%79 −19%110 −45%99 +13%
EBITDA15 13 46 15 3 −80%7 −46%16 −66%3 −78%
Net profit10 7 28 8 -3 −126%-5 −167%1 −96%-8 −199%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Capital allocation

high confidence
  • Capex ₹270 Cr
    • Greenfield Dahej facility for cooling agents, clove, eugenol, citral, and phenol derivatives, increasing total capacity to 16,000 MTPA (3x expansion) ₹270 Cr
    The total capital expenditure for the Dahej facility is approximately INR270 crores, of which around INR250 crores has already been incurred and largely capitalized. This facility will increase the company's total capacity to approximately 16,000 MTPA, representing an effective 3x expansion in capacity.

Guidance & targets

Revenue

  • Revenue target Revenue · FY28 · High confidence INR 1,050-1,100 crores
    The company is targeting revenue of INR1,050 crores to INR1,100 crores by FY '28, with EBITDA margins in the range of 16% to 18%.

    — Yash Parekh

  • Dahej facility peak revenue Revenue · FY29 · High confidence INR 750-800 crores
    at current expansion, I think, INR750 to INR800 crores is what we can reach in 2 to 3 years.

    — Suraj Shah

Profitability

  • EBITDA Margin target Profitability · FY28 · High confidence 16-18%
    The company is targeting revenue of INR1,050 crores to INR1,100 crores by FY '28, with EBITDA margins in the range of 16% to 18%.

    — Yash Parekh

  • Krystal (Dahej) cash breakeven Profitability · FY27 · High confidence Cash breakeven
    we expect Krystal to cash break even in the next year. ... somewhere in the range of 45% is when our calculations are that we should break even at like cash.

    — Suraj Shah

Capacity Utilization

  • Dahej facility utilization Capacity Utilization · Q1 FY28 · High confidence 50-60%
    the goal is to have all products come in, come online by like Q1 of next year. And then we observe our execution and we expect like 50%-60% by next year, by next year end.

    — Suraj Shah

Product Development

  • Catalyst preparation for Phenol Derivatives Product Development · Q4 FY26 · High confidence Completed
    For Phenol Derivatives, catalyst preparation is currently underway and is expected to be completed by the end of Q4 FY '26.

    — Yash Parekh

  • Trial production of Anisole, MEHQ, Guaiacol Product Development · Q1 FY27 · High confidence Planned
    Following this, trial production of Anisole, MEHQ and Guaiacol is planned for Q1 FY '27.

    — Yash Parekh

Revenue Contribution

  • Krystal (Dahej) revenue contribution Revenue Contribution · FY28 · Medium confidence INR 650-700 crores
    how that INR1100 crores may look like, and this can change, of course, given, but our sense is, it still would be like INR650 to INR700 from Krystal. The balance would be GEM.

    — Suraj Shah

  • GEM (Budaun/Silvassa) revenue contribution Revenue Contribution · FY28 · Medium confidence INR 400 crores
    the split that we see is INR700 by Krystal and INR400 by GEM.

    — Suraj Shah

What to watch in Q4 FY26

Dahej facility ramp-up and utilization

Q4 FY26 onwards, 50-60% by Q1 FY28
Current Limited contribution (20 days) in Q3 FY26
Target Meaningful contribution, progress towards 50-60% utilization

Why it matters

Crucial for achieving long-term revenue and margin targets, as it represents a 3x capacity expansion.

We expect a more meaningful contribution from Q4 FY '26 onwards as new products are launched and capacity ramp-up begins... we expect like 50%-60% by next year, by next year end.

Risks & concerns

  • External headwinds impacting revenue

    medium

    Revenues impacted by tariff-related uncertainty and GST-related changes, influencing customer procurement behavior and demand.

    Management acknowledged

  • Competition in MEHQ market

    medium

    Analyst noted new entrants like Vinati and existing players like Clean Science in MEHQ, but management expressed confidence in its technology and downstream derivatives.

    Analyst downplayed

  • Geopolitical factors affecting global scenarios

    medium

    Headwinds from changing global scenarios due to current geopolitics make the long due diligence process for customer approvals challenging.

    Management acknowledged

  • Higher depreciation impacting profitability

    low

    Profitability impacted by higher depreciation of INR 8.7 crores, a non-cash charge, following capitalization of Dahej capex.

    Management acknowledged

  • Limited initial contribution from new Dahej facility

    low

    Dahej facility's contribution was limited in Q3 FY26 due to operations being restricted to approximately 20 days post-commissioning.

    Management acknowledged

  • Impact of unorganized sector on GST

    low

    The GST issue is primarily with the unorganized and fragmented smaller suppliers/customers where price is the only consideration, and management feels it is here to stay for some time.

    Management acknowledged

Q&A highlights

6 direct, 1 evasive
Margin improvement drivers Partial
It is actually improving realizations compared to Q2. It is also coming in from our US subsidiary, which is GEM LLC, where realization and demand to the extent that some inventory has been exhausted with a few customers, they have started ordering, although at a slower pace. So, that also helps realizations come up and then the margins.

Analyst questioned the sharp margin rise, and management attributed it to improved realizations and contribution from the US subsidiary, indicating a demand recovery.

Asked by Kamlesh Bagmar

Krystal (Dahej) facility PAT positive timeline Direct
Right. So, I think, again, a lot of parts have to fall in place, but we expect Krystal to cash break even in the next year. ... somewhere in the range of 45% is when our calculations are that we should break even at like cash.

Management provided a clear timeline and utilization target for the new facility to achieve cash breakeven, crucial for future profitability.

Asked by Nishita

Dahej facility ramp-up and peak revenue Direct
the goal is to have all products come in, come online by like Q1 of next year. And then we observe our execution and we expect like 50%-60% by next year, by next year end. ... I meant we can reach the revenue of INR750 crores, INR800 crores in Krystal, which is like 3x the asset turn. So, like in three years out, the somewhere in FY '29, we can do that.

Management clarified the ramp-up schedule and the significant revenue potential from the Dahej facility, providing concrete targets for capacity utilization and revenue contribution.

Asked by Nishita

Phenol Derivative business strategy and competition Direct
our intent is to manufacture and produce the Anisole in-house to go ahead and give us the necessary cost competitive advantages for going downstream from there, towards MEHQ, Guaiacol... we are convinced about our technology... we emphasize that there should be not a significant challenge in selling what we are producing out here.

Management outlined its backward integration strategy for phenol derivatives, expressing confidence in its technology and ability to compete despite existing players, highlighting a focus on margin-accretive downstream products.

Asked by Disha

EU trade deal and current duties on Indian exports Evasive
there are about close to 80 products that we have. Each one clearly has a different import tax as it stands today. And we would need to kind of evaluate this on a much more holistic level once the EU trade deal, the contours of those trade deals are much more visible to all of us.

Management did not provide specific duty rates, indicating uncertainty and a wait-and-see approach regarding the impact of the upcoming India-EU trade deal on its diverse product portfolio.

Asked by Saiganesh

Cooling agent sales ramp-up and Q4 order booking Direct
expect that those audits to be completed, hopefully by March and April, and post which we would start seeing a ramp up in the sales for specifically the cooling agent range. ... much more inquiries and those order flows are expected to come in in Q4.

Management provided a timeline for the commercial ramp-up of cooling agents and indicated strong demand visibility for Q4, which is historically the strongest quarter.

Asked by Akshada Deo

Tariff risk mitigation strategies Direct
we are working on a dual one US plus one strategy from a standpoint of getting that approved. So even if the tariffs stay as they are, we are cognizant of this and we are taking all the necessary steps to ensure that it no longer becomes a major hurdle in the coming quarters.

Management detailed its proactive strategies, including a 'US plus one' approach and working with institutional buyers on facility approvals, to de-risk the business from tariff uncertainties.

Asked by Akshada Deo

Revenue contribution split between Krystal (Dahej) and GEM (existing facilities) Direct
the split that we see is INR700 by Krystal and INR400 by GEM. ... So cooling agents is exempt from tariffs as per annex II. Eugenol is exempt from US tariffs. Citral derivatives is largely an import substitution play. And phenol derivatives is also a mix between domestic and export, but non-US.

Management provided a clear breakdown of the expected revenue contribution from new and existing facilities towards the FY28 target, along with insights into the tariff status of key products for the US market.

Asked by Darshan Garg

2 min read 5 chapters

Detailed narrative

Q3 FY26 Financial Performance and Margin Improvement

In Q3 FY26, Gem Aromatics reported consolidated revenue from operations of INR 78.9 crores. Despite a net loss of INR 5 crores, primarily due to higher depreciation, the company demonstrated significant margin improvement. Consolidated Gross Profit margin expanded from 14% in Q2 FY26 to 23% in Q3 FY26, while consolidated EBITDA margin improved from 3% to 8.9% quarter-on-quarter. This margin expansion was attributed to improved realizations, a gradual recovery in mint prices, and better customer alignment.

Dahej Greenfield Facility Commissioning and Capacity Expansion

The company made significant progress at its Greenfield Dahej facility, which is a key pillar for long-term growth. The facility commissioned cooling agents (WS23 and WS03) and clove/eugenol verticals on December 11, 2025. With a total capital expenditure of approximately INR 270 crores (INR 250 crores already incurred), the Dahej plant will increase the company's total capacity to 16,000 MTPA, representing an effective 3x expansion. The plant has also successfully completed first-stage audits for various global compliance certifications.

Product Diversification and Phenol Derivatives Strategy

Gem Aromatics is expanding beyond its mint-centric business towards a diversified specialty ingredients platform. The Dahej facility will enable manufacturing capabilities across Clove and Clove Derivatives, Citral Derivatives, Phenol Derivatives, and Cooling Agents. For Phenol Derivatives, catalyst preparation is expected to be completed by Q4 FY26, with trial production of Anisole, MEHQ, and Guaiacol planned for Q1 FY27. The company intends to manufacture Anisole in-house to gain cost advantages for downstream products, focusing on margin-accretive derivatives for the flavor and fragrance industry.

Market Headwinds and Mitigation Strategies

Revenues in Q3 FY26 were impacted by external headwinds, including tariff-related uncertainty and GST-related changes, which influenced customer procurement behavior. The company noted that approximately 60% of its FY25 exports to the US market were under tariffs, causing pain. To mitigate these risks, Gem Aromatics is pursuing a 'dual US plus one' strategy, focusing on tariff-exempt products for the US and expanding exposure to the European markets, anticipating benefits from the India-EU trade deal.

Long-term Growth Outlook and Targets

The company is confident in its growth trajectory, targeting revenue of INR 1,050-1,100 crores by FY28, with EBITDA margins in the range of 16-18%. The Dahej facility is expected to reach 50-60% utilization by Q1 FY28 and generate INR 750-800 crores in revenue by FY29, based on a 3x asset turnover. Krystal (Dahej) is projected to achieve cash breakeven by FY27 at approximately 45% capacity utilization, contributing INR 650-700 crores to the FY28 revenue target, with the remaining INR 400 crores from existing GEM facilities.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Chemicals earnings calls